<code id='C2EF8EE2A0'></code><style id='C2EF8EE2A0'></style>
    • <acronym id='C2EF8EE2A0'></acronym>
      <center id='C2EF8EE2A0'><center id='C2EF8EE2A0'><tfoot id='C2EF8EE2A0'></tfoot></center><abbr id='C2EF8EE2A0'><dir id='C2EF8EE2A0'><tfoot id='C2EF8EE2A0'></tfoot><noframes id='C2EF8EE2A0'>

    • <optgroup id='C2EF8EE2A0'><strike id='C2EF8EE2A0'><sup id='C2EF8EE2A0'></sup></strike><code id='C2EF8EE2A0'></code></optgroup>
        1. <b id='C2EF8EE2A0'><label id='C2EF8EE2A0'><select id='C2EF8EE2A0'><dt id='C2EF8EE2A0'><span id='C2EF8EE2A0'></span></dt></select></label></b><u id='C2EF8EE2A0'></u>
          <i id='C2EF8EE2A0'><strike id='C2EF8EE2A0'><tt id='C2EF8EE2A0'><pre id='C2EF8EE2A0'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:focus    Page View:2464
          Glaxo Smith Kline
          Akira Suemori/AP

          A few years ago, Vijay Pande, then a professor at Stanford who was using computer science to understand biology, was deciding whether to leave full-time academic work to become a venture capitalist. He turned to Andrew Ng, another Stanford professor who had joined Google Brain and later the Chinese search firm Baidu.

          “The things that we dreamed about five or 10 years ago were happening now,” Pande recalled Ng telling him. “The question was, do you want to be a part of it? Or do you want to write another paper?”

          advertisement

          Pande decided to become a venture capitalist. The result, he told an audience at a STAT event in San Francisco last week, is that, whereas he managed about $1 million to $2 million in research as a top academic, he now works at the fabled Silicon Valley firm Andreessen Horowitz, which invests $100 million a year.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In
          Previous article: Vertex non
          Next article: In Memoriam: Notable people who died in 2023

          comprehensive

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          J&J to emphasize cancer drugs, stop much of its vaccine research
          J&J to emphasize cancer drugs, stop much of its vaccine research

          DanielHulshizer/APEightmonthsintohistenure,Johnson&Johnson’sR&Dchiefisputtingabigemphasisonm

          read more
          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more

          Merck CEO won’t testify in Senate, citing no expertise in drug prices

          Sen.BernieSanderstoldreportersthatMerck'sCEOrefusedtotestifyoveralackofexpertiseindrugpricing.Mariam